Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data.
Jensen LR, Maier AD, Lomstein A, Graillon T, Hrachova M, Bota D, Ruiz-Patiño A, Arrieta O, Cardona AF, Rudà R, Furtner J, Roeckle U, Clement P, Preusser M, Scheie D, Broholm H, Kristensen BW, Skjøth-Rasmussen J, Ziebell M, Munch TN, Fugleholm K, Walter MA, Mathiesen T, Mirian C. Jensen LR, et al. Among authors: arrieta o. Neurosurg Rev. 2022 Oct;45(5):3067-3081. doi: 10.1007/s10143-022-01849-6. Epub 2022 Aug 19. Neurosurg Rev. 2022. PMID: 35984552 Review.
KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making.
Campos-Parra AD, Zuloaga C, Manríquez ME, Avilés A, Borbolla-Escoboza J, Cardona A, Meneses A, Arrieta O. Campos-Parra AD, et al. Among authors: arrieta o. Am J Clin Oncol. 2015 Feb;38(1):33-40. doi: 10.1097/COC.0b013e318287bb23. Am J Clin Oncol. 2015. PMID: 23538866
The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer.
Arrieta O, Cardona AF, Corrales L, Campos-Parra AD, Sánchez-Reyes R, Amieva-Rivera E, Rodríguez J, Vargas C, Carranza H, Otero J, Karachaliou N, Astudillo H, Rosell R; CLICaP. Arrieta O, et al. Lung Cancer. 2015 Feb;87(2):169-75. doi: 10.1016/j.lungcan.2014.12.009. Epub 2014 Dec 18. Lung Cancer. 2015. PMID: 25558790
Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
Cardona AF, Rojas L, Wills B, Arrieta O, Carranza H, Vargas C, Otero J, Cuello M, Corrales L, Martín C, Ortiz C, Franco S, Rosell R; CLICaP. Cardona AF, et al. Among authors: arrieta o. PLoS One. 2016 May 18;11(5):e0154293. doi: 10.1371/journal.pone.0154293. eCollection 2016. PLoS One. 2016. PMID: 27191954 Free PMC article.
The safety of afatinib for the treatment of non-small cell lung cancer.
Barron F, de la Torre-Vallejo M, Luna-Palencia RL, Cardona AF, Arrieta O. Barron F, et al. Among authors: arrieta o. Expert Opin Drug Saf. 2016 Nov;15(11):1563-1572. doi: 10.1080/14740338.2016.1236910. Epub 2016 Sep 28. Expert Opin Drug Saf. 2016. PMID: 27633264 Review.
Ramucirumab in the treatment of non-small cell lung cancer.
Arrieta O, Zatarain-Barrón ZL, Cardona AF, Carmona A, Lopez-Mejia M. Arrieta O, et al. Expert Opin Drug Saf. 2017 May;16(5):637-644. doi: 10.1080/14740338.2017.1313226. Epub 2017 Apr 21. Expert Opin Drug Saf. 2017. PMID: 28395526 Review.
362 results